1. Digital design and manufacturing of the Lingualcare bracket system.
Mujagic M., Fauquet C., Galletti C., Palot C., Wiechmann D., Mah J.
J Clin Orthod200539:6(375-382; quiz 370) MEDLINE [No abstract available]

2 2. Circulating levels of prolactin in breast cancer patients.
Mujagić Z., Mujagić H., Prnjavorac B.
Med Arh200559:1(33-35) MEDLINE
3 3. Importance of serum prolactin determination in metastatic breast cancer patients
Mujagić Z., Mujagić H.
Croat. Med. J.200445:2(176-180) EMBASE
4 4. Inhalation of gasoline and damage to health in workers at gas stations
Pranjić N., Mujagić H., Pavlović S.
Med Arh200357:1(17-20) MEDLINE
5 5. Alcohol in alcoholic liver disease is a causative factor for development of allergic skin manifestations.
Mujagić H., Prnjavorac B., Mujagic Z., Festa G.
Med Arh200357:5-6(273-278) MEDLINE
6 6. Mechanisms of action and potential therapeutic uses of thalidomide
Mujagić H., Chabner B.A., Mujagić Z.
Croat. Med. J.200243:3(274-285) EMBASE
7 7. Precarcinoma and early carcinomatous lesions in the uterine cervix and the use of oral contraceptives
Ljuca D., Fatusić Z., Mujagić H., Ljuca F., Alispahić N.
Med Arh200054:2(71-73) MEDLINE
8 8. Quality of medical records as a basis for DRG classification in the health care system in Bosnia-Herzegovina
Sabanović Z., Mujagić H., Bazardzanović M.
Med Arh199953:3 Suppl 3(61-64) MEDLINE
9 9. Detection of pleiotropic drug resistance by the rapid immunofluorescence assay of drug effects on the cell skeleton
Mujagic H., Mujagic Z.
ONCOLOGY199148:3(202-209) EMBASE
10 10. The levels and relations of prostaglandins in pregnant and non-pregnant tumor-bearing mice
Mujagic H., Krnjajic N., Jevric A.
J. CANCER RES. CLIN. ONCOL.1989115:4(383-387) EMBASE
11 11. Comparison of PGE1 and PGE2 levels in pregnant syngeneic BALB/C mice with transplanted fibrosarcoma.
Krnjaić N., Jevrić A., Krnjaić Z., Filipović I., Mujagić H.
Prog Clin Biol Res1987242:-(119-122) MEDLINE
12 12. Quantitative changes in surface immunoglobulin expression in WEHI-231 lymphoma cells in relation to their proliferative rate
Mujagic H., Shackney S.E., Smith C.E., Chen S.S.
ONCOLOGY198643:4(237-242) EMBASE
13 13. Detection of pleiotropic drug resistance (PDR) by immunofluorescent assay of drug effects on cytoskeleton
Mujagic H., Hamel E., Curt G., Chabner B.A.
14 14. Schedule dependence of vincristine lethality in Sarcoma 180 cells following partial synchronization with hydroxyurea
Mujagic H., Conger B.M., Smith C.A.
CANCER RES.198343:8(3598-3603) EMBASE
15 15. Effects of vincristine on cell survival, cell cycle progression, and mitotic accumulation in asynchronously growing sarcoma 180 cells
Mujagic H., Chen S.S., Geist R.
CANCER RES.198343:8(3591-3597) EMBASE
16 16. Studies on the lethal and sublethal effects of vincristine (VCR) in sarcoma 180 in vitro
Conger B., Occhipinti S.J., Mujagic H.
17 17. The significance of tuberculin immunity testing in cancer patients
Mujagic H., Deskovic M., Malenica B.
CELL. MOL. BIOL.198026:2(111-121) EMBASE
18 18. BCG immunotherapy in previously treated malignant melanoma patients
Mujagic H., Kolaric K., Malenica B., Nola P.
BIOMEDICINE197930:2(95-102) EMBASE
19 19. Possibilities of immunotherapy of malignant tumors in men
Mujagic H.
MED. ARH.197832:1(43-49) EMBASE
20 20. Possibilities of immunotherapy in malignant tumors in man
Mujagić H.
Med Arh197832:1(43-49) MEDLINE
21 21. In vitro detection of cellular immunity to melanoma antigens in man by the monocyte spreading inhibition test
Mazuran R., Mujagic H., Malenica B., Silobrcic V.
INT. J. CANCER197617:1(14-20) EMBASE
22 22. The effect of splenectomy on fibrosarcoma "metastases" in lungs of mice.
Milas L., Mujagic H.
Int J Cancer197311:1(186-190) MEDLINE
23 23. Experimental lung metastases as a test in tumour immunology
Silobrcic V., Milas L., Mujagic H.
IARC SCI. PUBL.1973vol.7:-(411-417) EMBASE
24 24. Protection by Corynebacterium parvum against tumour cells injected intravenously.
Milas L., Mujagić H.
Rev Eur Etud Clin Biol197217:5(498-500) MEDLINE

 Powered by ORBUS Belgium